doi:10.3969/j.issn.1671-2587.2023.02.002

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2023, Vol. 25 ›› Issue (2): 163-169.DOI: 10.3969/j.issn.1671-2587.2023.02.002

Previous Articles Next Articles

Received:2023-03-13 Published:2023-04-25

[1] 中华医学会血液学分会红细胞疾病学组,赖永榕,李莉娟,等.非输血依赖型地中海贫血诊断与治疗中国专家共识(2018年版)[J].中华血液学杂志,2018,39(9):705-708.
[2] CAPPELLINI MD, FARMAKIS D, PORTER J, et al.2021 Guidelines for the management of transfusion dependent thalassaemia (TDT).4th.[M].Cyprus: Thalassaemia International Federation, 2021: 38-51.
[3] 方建培,尹晓林,兰和魁,等.儿童非输血依赖型地中海贫血的诊治和管理专家共识[J].中国实用儿科杂志,2018,33(12):929-934.
[4] 中华医学会医学遗传学分会遗传病临床实践指南撰写组,商璇,吴学东,等. β-地中海贫血的临床实践指南[J].中华医学遗传学杂志,2020,37(3): 243-251.
[5] 中华医学会医学遗传学分会遗传病临床实践指南撰写组, 商璇, 张新华, 等. α-地中海贫血的临床实践指南[J].中华医学遗传学杂志,2020,37(3): 235-242.
[6] 全国血红蛋白病研究协作组, 陈人骏.20省、市、自治区60万人血红蛋白病调查[J] .中华医学杂志,1983,63( 06 ): 382-385.
[7] ZHAI L,LIU Y H,HUO R R,et al.Long-term effect of hematopoietic stem cell transplantation on the quality of life of patients with β-thalassemia major in Guangxi,China—a cross-sectional study[J].Curr Stem Cell Res Ther,2022.
[8] 中华医学会血液学分会红细胞疾病(贫血)学组.中国输血依赖型β地中海贫血诊断与治疗指南(2022年版)[J].中华血液学杂志,2022,43(11):889-896.
[9] CHENG C K,LEE C K,LIN C K.Clinically significant red blood cell antibodies in chronically transfused patients:a survey of Chinese thalassemia major patients and literature review[J].Transfusion,2012,52(10):2220-2224.
[10] SHAO C P,ZHAO C J,WU C L,et al.Rh-matched transfusion through molecular typing for β-thalassemia patients is required and feasible in Chinese[J].Transfus Med Hemother,2018,45(4):252-257.
[11] WALDIS S J,UTER S,KAVITSKY D,et al.Rh alloimmunization in chronically transfused patients with thalassemia receiving RhD,C,E,and K matched transfusions[J].Blood Adv,2021,5(3):737-744.
[12] 中华医学会儿科学分会血液学组,《中华儿科杂志》编辑委员会.重型β地中海贫血的诊断和治疗指南(2017年版)[J].中华儿科杂志,2018,56(10):724-729.
[13] Atkins D, Best D, Briss PA, et al.Grading quality of evidence and strength of recommendations[J].BMJ,2004,328(7454):1490.
[14] CAPPRLLINI MD 主编;余艳红,钟梅主译.输血依赖性地中海贫血的管理指南[M].北京:人民卫生出版社,2019.
[15] TAHER A T,MUSALLAM K M,CAPPELLINI M D.β-thalassemias[J].N Engl J Med,2021,384(8):727-743.
[16] 中华人民共和国国家卫生健康委员会.儿科输血指南[S].2022.
[17] 方建培,许吕宏.规范儿童重型β地中海贫血的诊治[J].中华儿科杂志,2010,48(3):166-169.
[18] MUSALLAM K M,CAPPELLINI M D,VIPRAKASIT V,et al.Revisiting the non-transfusion-dependent (NTDT) vs.transfusion-dependent (TDT) thalassemia classification 10 years later[J].Am J Hematol,2021,96(2):E54-E56.
[19] TAHER A T,WEATHERALL D J,CAPPELLINI M D.Thalassaemia[J].Lancet,2018,391(10116):155-167.
[20] 伍昌林,王小华,何建安,等.长期输血的重型β地中海贫血患儿RH因子与临床输血有效性研究[J].中国实验血液学杂志,2015,23(6):1657-1661.
[21] WU C L,HUANG G Q,YI P,et al.Alloantibodies,specificities,and alloimmunization outcomes through Rh extended matching transfusion for thalassemia patients[J].Clin Lab,2022,68(4): 654-658.
[22] 伍昌林,邵超鹏,张印则,等.毛细管离心法在定期输血地中海贫血患者RhCcEe血型鉴定中的应用[J].中国输血杂志,2020,33(6):555-558.
[23] TEAWTRAKUL N,SONGDEJ D,HANTAWEEPANT C,et al.Red blood cell alloimmunization and other transfusion-related complications in patients with transfusion-dependent thalassemia:a multi-center study in Thailand[J].Transfusion,2022,62(10):2039-2047.
[24] CHAO Y H,WU K H,LU J J,et al.Red blood cell alloimmunisation among Chinese patients with β-thalassaemia major in Taiwan[J].Trasfusione Del Sangue,2013,11(1):71-74.
[25] WU C L,YI P,SHAO C P.A novel RHCE*cE allele identified in a Chinese individual,encodes weakened expression of c and E antigens[J].Transfus Apher Sci,2022,61(1):103295.
[26] MUSALLAM K M,ANGASTINIOTIS M,ELEFTHERIOU A,et al.Cross-talk between available guidelines for the management of patients with beta-thalassemia major[J].Acta Haematol,2013,130(2):64-73.
[27] ROMPHRUK A V,SIMTONG P,BUTRYOJANTHO C,et al.The prevalence,alloimmunization risk factors,antigenic exposure,and evaluation of antigen-matched red blood cells for thalassemia transfusions:a 10-year experience at a tertiary care hospital[J].Transfusion,2019,59(1):177-184.
[28] POLITOU M,KOMNINAKA V,VALSAMI S,et al.The effect of transfusion on immune responses in thalassemia[J].Blood Cells Mol Dis,2020,83:102425.
[29] ZENGIN ERSOY G,AYÇIÇEK A,ODAMAN AL I,et al.Safety and efficacy of deferasirox in patients with transfusion-dependent thalassemia:a 4-year single-center experience[J].Pediatr Hematol Oncol,2021,38(6):555-563.
[30] 中华医学会血液学分会红细胞疾病(贫血)学组.自身免疫性溶血性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(4):265-267.
[31] COHN CS, DELANEY M, JOHNSON ST, et al.Technical Manual (AABB), 20th Edition[M].Bethesda: American Association of Blood Banks.2020: 771.
[32] WHEELER M M,JOHNSEN J M.The role of genomics in transfusion medicine[J].Curr Opin Hematol,2018,25(6):509-515.
[33] WILLIAMS T N,WEATHERALL D J.World distribution,population genetics,and health burden of the hemoglobinopathies[J].Cold Spring Harb Perspect Med,2012,2(9):a011692.
[34] FARMAKIS D,GIAKOUMIS A,ANGASTINIOTIS M,et al.The changing epidemiology of the ageing thalassaemia populations:a position statement of the Thalassaemia International Federation[J].Eur J Haematol,2020,105(1):16-23.
[35] ANGELUCCI E,BRITTENHAM G M,MCLAREN C E,et al.Hepatic iron concentration and total body iron stores in thalassemia major[J].N Engl J Med,2000,343(5):327-331.
[36] YARDUMIAN A,TELFER P,DARBYSHIRE P.Standards for the clinical care of children and adults with thalassaemia in the UK[M].2nd edition.London:United Kingdom ThalassaemiaSociety,2008.
[37] 刘容容. 铁过载对地中海贫血患者造血功能的损伤和机制研究[J].广西医科大学学报,2019,36(6):1018-1021.
[38] FARMAKIS D,PORTER J,TAHER A,et al.2021 thalassaemia international federation guidelines for the management of transfusion-dependent thalassemia[J].Hemasphere,2022,6(8):e732.
[39] ELALFY M S,ADLY A,AWAD H,et al.Safety and efficacy of early start of iron chelation therapy with deferiprone in young children newly diagnosed with transfusion-dependent thalassemia:a randomized controlled trial[J].Am J Hematol,2018,93(2):262-268.
[40] CHUANG T Y,LI J P,WENG T F,et al.Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications[J].Ann Hematol,2020,99(10):2289-2294.

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	. [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 170-179.
[2]	. [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 180-184.
[3]	FAN Feng-yan, MA Yue-yun. The Selection of RhD Blood Type in Blood Transfusion of RhD Mismatched Allogeneic Hematopoietic Stem Cell Transplantation [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 189-192.
[4]	YUAN Hai-qing, JING Hong-li, ZHU Li-li, et al. Discussion on the Current Situation of Red Blood Cell Component Blood Inventory Management in 26 Local and Municipal Blood Stations in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 204-209.
[5]	XU Lan, GUO He-long, ZHU Li-li, et al. Productivity Analysis of Red Blood Cell Products in 20 Central Blood Stations in China [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 210-214.
[6]	WANG Rui-han, PENG Juan, LIU Hao, et al. Effects of Intraoperative Cell Salvage on Coagulation and Fetal Components in High-risk Cesarean Section [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 215-219.
[7]	HU Yi-fan, HUANG Li-ping, LIU Yi-quan. Video Stimulation Test Prevents the Vagus Nerve Reaction Related to Blood Donation Caused by Anxiety [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 230-234.
[8]	ZHU Yu-li, AN Run, FENG Zhi-hui. Identification of Rare Di(b-) Blood Group by TaqMan-MGB Real-time PCR [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 235-238.
[9]	. [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 273-276.
[10]	GE Shuang, WANG De-qing. Research Advances in Transfusion Medicine 2021-2022 [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(2): 276-281.
[11]	QING Yun, ZHOU Qiong, PENG Kai, et al. Performances of Platelet Storage in SSP+ Additive Solution versus Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 698-704.
[12]	MAO Ping-ping, WANG Shu-jun, LUO Kai-yun, et al. Study on the Antibacterial Effect of Frozen Platelet-rich Plasma and Lyophilized Platelet-rich Plasma [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 705-709.
[13]	CHEN Rui, LV Meng-xing, YIN Jia-zhong, et al. The Transfusion Management in Children with Thalassemia：Safety Strategies in Yunnan Province [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 710-715.
[14]	XIE Hui-yi, ZHOU Zai-xin, YANG Yue, et al. Analysis of the Influence of Anti-M Antibody on Blood Group Identification and Clinical Blood Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 716-720.
[15]	HU Heng-ya, ZHOU Xiao-yu. The Effect of Preoperative Anemia on Perioperative Transfusion and Postoperative Outcomes in Children with Congenital Heart Disease [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2022, 24(6): 721-724.